Download Citation
Article Source:
Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab
Heine RJSD,
Thielen FW,
Mathijssen RHJ,
van Leeuwen RWF,
Franken MG,
et al.
(2024)
Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.
PLOS ONE 19(2): e0293264.
https://doi.org/10.1371/journal.pone.0293264